Page 4 - PROPOSAL LATIP Zanamivir_Neat 2

The drug delivery system, which includes large particle-sized materials, poses

many problems to the delivery system and absorption of the drug. This problem includes
in vivo instability, poor bioavailability, poor solubility, poor absorption in the body,

issues with target-specific delivery, tonic effectiveness, and probable adverse effects of
drugs (Patra et al., 2018).

1.3 Research objectives

1.3.1 General objective
To design and develop Zanamivir nanoparticles for enhanced oral delivery that is

subjected to physicochemical characterization study, in vitro drug release study, in vitro

diffusion chamber study, in vivo oral absorption study and mechanism of drug transport
across the intestinal linings. To design and formulate a new and novel delivery system to

increase bioavailability of the drug as well as to study its mechanistic pathways on the
absorption profiles of zanamivir.

1.3.2 Specific objectives are:

1) formulation development of Zanamivir nanoparticles formulation using ionic

gelation technique. Formulation with the smallest size and most stable in terms of
PDI and zeta potential values will be selected for subsequent studies.

2) characterization study encompasses particle size analysis, polydispersity index
(PDI), morphology study (SEM and TEM), FTIR, XRD.

3) to perform Caco-2 cell permeation study.

4) to perform in vitro drug release study and encapsulation efficiency study (EE).
5) to determine Zanamivir nanoparticle drug transport across the intestinal linings

(from apical to basolateral side) using in vitro diffusion chamber study.
6) to examines the mechanism of Zanamivir transport via transepithelial electrical

resistance (TEER) analysis.

7) to conduct HPLC method development and validation of Zanamivir for oral
delivery.
8) to conduct in vivo oral and nasal absorption study of Zanamivir nanoparticles in

Spraque Dawley model rats.

1.4 Significant of study